On March 22, 2022 Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, reported that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in the following upcoming virtual investor conferences in March (Press release, Decibel Therapeutics, MAR 22, 2022, View Source [SID1234610578]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference:

Dr. Reid will participate in a fireside chat, which will be available for on-demand viewing starting on Wednesday, March 30, 2022 at 7:00 a.m. ET.
Dr. Reid will also participate in a panel discussion titled, "Unlocking the path to hearing restoration with gene therapy" on Wednesday, March 30, 2022 at 1:00 p.m. ET.
Cantor Fitzgerald Virtual Rare Orphan Disease Summit:

Dr. Reid will participate in a panel discussion titled, "Gene Therapy Pioneers: Why Experience Matters When Targeting Rare Diseases" on Tuesday, March 29, 2022 at 4:00 p.m. ET. The live panel may be accessed by conference attendees through the conference portal.
Webcasts of the H.C. Wainwright fireside chat and panel may be accessed by visiting the Investors section of the Decibel Therapeutics website at View Source An archived replay of the webcasts will be available on the Company’s website for approximately 90 days following the fireside chat.